Gain Therapeutics, Inc. (GANX) Key Metrics
GANX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $55.0M
- Enterprise value
- $68.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 255.5 10-yr median 334.5
- Price / book
- 7.1 10-yr median 3.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.19
GANX key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGANX valuation Price multiples at each fiscal year-end price.
Price / book−15.1%
5.7
2025 · hover or tap a bar for each year
20182025
Free cash flow yield+20.8 pts
−17.4%
2025 · hover or tap a bar for each year
20182025
GANX returns How much profit the business earns on the capital it uses.
Return on equity+49.3 pts
−155.7%
2025 · hover or tap a bar for each year
20182025
Return on assets+17.4 pts
−115.4%
2025 · hover or tap a bar for each year
20182025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20182025
GANX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20182025
Earnings per share
−$0.61
2025 · hover or tap a bar for each year
20182025
Free cash flow per share
−$0.56
2025 · hover or tap a bar for each year
20182025
Book value per share+75.6%
$0.56
2025 · hover or tap a bar for each year
20182025
Shares outstanding+44.1%
33.0M
2025 · hover or tap a bar for each year
20182025
GANX financial health Debt, liquidity and how easily interest is covered.
Debt / equity−55.7%
0.04
2025 · hover or tap a bar for each year
20182025
Net debt−$10.4M
−$20.1M
2025 · hover or tap a bar for each year
20182025
Current ratio+123.6%
6.63
2025 · hover or tap a bar for each year
20182025
Debt / assets−40.4%
0.03
2025 · hover or tap a bar for each year
20182025
GANX efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−1,480 days
3,437 days
2025 · hover or tap a bar for each year
20182025
GANX valuation history
Fiscal year-endToday8-year median
GANX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GANX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GANX price vs earnings per share
Share price at year-endEPS (right axis)
GANX key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $106.2M | $49.4M | $42.5M | $37.2M | $55.2M | — | — | — |
| Enterprise value | $86.1M | $39.7M | $26.7M | $18.3M | $19.9M | — | — | — |
| Price / sales | — | — | 769.9 | 265.5 | 334.5 | — | — | — |
| Price / book | 5.7 | 6.7 | 3.4 | 2.0 | 1.6 | — | — | — |
| EV / sales | — | — | 484.1 | 130.8 | 120.8 | — | — | — |
| Earnings yield | −19.0% | −41.3% | −52.4% | −47.3% | −25.2% | — | — | — |
| Free cash flow yield | −17.4% | −38.2% | −44.4% | −39.8% | −22.6% | — | — | — |
| Share price at fiscal year-end | $3.22 | $2.16 | $3.27 | $3.13 | $5.43 | — | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.02 | $0.00 | — | — |
| Earnings per share | −$0.61 | −$0.89 | −$1.71 | −$1.48 | −$1.37 | −$0.30 | — | — |
| Operating cash flow per share | −$0.56 | −$0.82 | −$1.45 | −$1.24 | −$1.22 | −$0.27 | — | — |
| Free cash flow per share | −$0.56 | −$0.83 | −$1.45 | −$1.25 | −$1.23 | −$0.27 | — | — |
| Cash per share | $0.63 | $0.45 | $1.29 | $1.69 | $3.63 | $0.63 | — | — |
| Book value per share | $0.56 | $0.32 | $0.97 | $1.59 | $3.43 | $0.52 | — | — |
| Tangible book value per share | $0.56 | $0.31 | $0.95 | $1.57 | $3.41 | $0.52 | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.00 | — | — |
| Debt per share | $0.02 | $0.03 | $0.08 | $0.11 | $0.16 | $0.11 | — | — |
| Shares outstanding | 33.0M | 22.9M | 13.0M | 11.9M | 10.2M | 11.9M | — | — |
| Change in shares outstanding | +44.1% | +75.9% | +9.5% | +16.9% | −14.4% | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −155.7% | −205.0% | −141.6% | −65.5% | −67.7% | −124.4% | — | — |
| Return on assets (ROA) | −115.4% | −132.8% | −104.3% | −55.8% | −57.2% | −69.7% | −298.0% | −136.2% |
| Return on tangible assets | −88.8% | −170.2% | −120.9% | −73.6% | −35.8% | −37.3% | −332.2% | −136.2% |
| Financial health | ||||||||
| Total debt | $732,067 | $653,015 | $1.0M | $1.3M | $1.6M | $1.3M | $200,950 | $1.3M |
| Cash & short-term investments | $20.8M | $10.4M | $16.8M | $20.1M | $36.9M | $7.5M | $303,320 | $400,694 |
| Net debt | −$20.1M | −$9.7M | −$15.8M | −$18.9M | −$35.3M | −$6.2M | −$102,370 | $904,670 |
| Debt / equity | 0.04 | 0.09 | 0.08 | 0.07 | 0.05 | 0.20 | — | — |
| Debt / assets | 0.03 | 0.05 | 0.06 | 0.05 | 0.04 | 0.13 | 0.30 | 1.61 |
| Current ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 | 4.25 | 0.45 | 0.93 |
| Quick ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 | 3.61 | 0.42 | 0.93 |
| Interest coverage | — | — | — | -71.9 | -117.3 | -18.4 | -102.2 | -19.6 |
| Working capital | $18.9M | $7.7M | $12.8M | $17.0M | $35.2M | $6.9M | −$481,005 | −$36,148 |
| Invested capital | −$1.5M | −$2.4M | −$3.2M | $15,206 | −$454,643 | −$29,559 | −$552,226 | −$46,238 |
| Tangible asset value | $18.5M | $7.2M | $12.4M | $18.7M | $34.6M | $6.2M | −$449,856 | −$950,908 |
| Net current asset value | $18.0M | $6.8M | $11.7M | $15.9M | $33.6M | $5.6M | −$712,095 | −$1.3M |
| Graham net-net per share | $0.52 | $0.27 | $0.84 | $1.26 | $3.23 | $0.40 | — | — |
| Capital allocation | ||||||||
| Capex / revenue | — | — | 27.8% | 84.9% | 57.1% | 72.1% | 33.2% | 38.8% |
| Capex / depreciation | 0.00 | 0.27 | 0.18 | 1.85 | 6.08 | 2.17 | 5.34 | 10.78 |
| Stock-based compensation / revenue | — | — | 5,906.2% | 1,089.5% | 508.7% | 282.7% | 0.0% | — |
| R&D / revenue | — | — | 20,878.2% | 5,979.2% | 4,342.1% | 7,822.5% | 3,840.7% | 4,012.2% |
| SG&A / revenue | — | — | 19,632.5% | 6,979.5% | 4,144.6% | 4,325.1% | 1,344.2% | 1,077.4% |
| Efficiency | ||||||||
| Days sales outstanding | — | — | 1,145.8 | 389.9 | 225.6 | 337.8 | 383.1 | 740.2 |
| Days of inventory on hand | — | — | — | — | — | 112.2 | — | — |
| Days payables outstanding | 3,437.3 | 4,917.3 | 6,686.5 | 48.4 | 38.8 | 90.1 | — | — |
| Cash conversion cycle (days) | — | — | -5,540.7 | 341.5 | 186.9 | 359.9 | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.32 | 0.94 | 1.62 | 1.08 | 0.95 | 0.49 |
| Payables turnover | 0.11 | 0.07 | 0.05 | 7.54 | 9.41 | 4.05 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | — | 3.25 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.03 |
| Average receivables | $784,228 | $504,170 | $173,227 | $149,662 | $101,998 | $26,732 | $43,354 | $41,794 |
| Average payables | $885,643 | $1.1M | $1.5M | $1.1M | $760,998 | $557,978 | $151,887 | $149,333 |
| Average inventory | — | — | — | — | — | $694,423 | $31,478 | — |
| Intangibles / total assets | 0.5% | 1.1% | 1.0% | 0.9% | 0.5% | 0.0% | 0.0% | 0.0% |
Computed from GANX's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GANX valuation and financial ratios
Gain Therapeutics earned a return on equity of −155.7% in fiscal 2025. It ended the year with $0.7 million of debt and $20.8 million in cash and short-term investments, a net cash position of $20.1 million.
See the GANX income statement, the GANX chart for price history, or the GANX stock overview for the latest quote and news.
GANX key metrics FAQ
What is Gain Therapeutics's return on equity?
Gain Therapeutics's return on equity (ROE) was −155.7% in fiscal 2025: net income of -$20.2 million on average shareholders' equity of $13.0 million.
How much debt does Gain Therapeutics have?
Gain Therapeutics had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Gain Therapeutics's free cash flow yield?
Gain Therapeutics generated -$18.5 million of free cash flow in fiscal 2025, a free cash flow yield of −17.4% on its market value at year-end ($106.2 million).
What is Gain Therapeutics's current ratio?
Gain Therapeutics's current ratio was 6.63 at the end of fiscal 2025: current assets were 6.63 times current liabilities.